Lijiang Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lijiang Sun has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Guiming Zhang
Department of Urology, The Affiliated Hospital of Qingdao University, China
14 shared publications Lei Luo
Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China
9 shared publicationsYao Zhu
Department of Urology, Fudan University Shanghai Cancer Center, No. 270, Dongan Rd., Shanghai, 200023, People's Republic of China
7 shared publications- Dahai Dong
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China
5 shared publications Gui-Ming Zhang
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, China
5 shared publications- Dingwei Ye
Department of Urology, Fudan University Shanghai Cancer Center
4 shared publications
Latest Publications
- 13 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218675
A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness
- 13 June 2026
- Published by Elsevier in Cancer Letters
- Vol. 656, 218675
A blood-urine regulatory axis: Tumor-derived factors reprogram urine-derived stem cells via CXCL2/CXCR2/ERK signaling to drive bladder cancer stemness
- Open Access
- 9 April 2026
- Published by Scientific Scholar in Cytojournal
- Vol. 23
Fibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer
Objectives: The role of fibrinogen-like protein 1 (FGL1) in the immune microenvironment in bladder cancer has been extensively studied, but the specific regulatory pathways require further investigation. Materials and Methods: The overexpression vector of FGL1 or small interfering RNA was transfected into RT4 cells, and cell growth was observed. Tumor cells with altered FGL1 expression were co-incubated with peripheral blood mononuclear cells to simulate the immune microenvironment of bladder cancer in vitro , and the number and function of immune cells were monitored. The potential interacting proteins of FGL1 were predicted using an online bioinformatics database. Fibronectin 1 (FN1) was selected as the follow-up research object and was overexpressed or knocked down to explore its effect on tumor cell growth and immune microenvironment. A mouse model of transplanted tumor in vitro was established to explore FGL1 knockdown on tumor growth and immune microenvironment in vivo . Results: FGL1 was abnormally overexpressed in bladder cancer and enhanced RT4 cells’ migration, invasion, and proliferation. Its knockdown inhibited tumor cell growth. FGL1 decreased CD4 and CD8+T cell proportion, increased the number of Treg cells, promoted CD8+T cell apoptosis, inhibited interferon-gamma, and upregulated the secretion level of interleukin-10. Its knockdown had the opposite effect. FN1 was identified as an interacting protein of FGL1 and was positively regulated by FGL1 to promote the growth of RT4 cells. In the FGL1-induced tumor immunosuppressive microenvironment, blocking FN1 reversed the situation. In vivo studies showed that FGL1 silencing inhibited the growth of subcutaneously transplanted tumors in mice, which was related to the inhibition of FGL1 and FN1 expression. Conclusion: FGL1 promotes bladder cancer immune evasion by upregulating FN1. Our results provide a new reference for the immunotherapy of bladder cancer.
- 9 April 2026
- Published by Scientific Scholar in Cytojournal
- Vol. 23
Open AccessFibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer
Objectives: The role of fibrinogen-like protein 1 (FGL1) in the immune microenvironment in bladder cancer has been extensively studied, but the specific regulatory pathways require further investigation. Materials and Methods: The overexpression vector of FGL1 or small interfering RNA was transfected into RT4 cells, and cell growth was observed. Tumor cells with altered FGL1 expression were co-incubated with peripheral blood mononuclear cells to simulate the immune microenvironment of bladder cancer in vitro , and the number and function of immune cells were monitored. The potential interacting proteins of FGL1 were predicted using an online bioinformatics database. Fibronectin 1 (FN1) was selected as the follow-up research object and was overexpressed or knocked down to explore its effect on tumor cell growth and immune microenvironment. A mouse model of transplanted tumor in vitro was established to explore FGL1 knockdown on tumor growth and immune microenvironment in vivo . Results: FGL1 was abnormally overexpressed in bladder cancer and enhanced RT4 cells’ migration, invasion, and proliferation. Its knockdown inhibited tumor cell growth. FGL1 decreased CD4 and CD8+T cell proportion, increased the number of Treg cells, promoted CD8+T cell apoptosis, inhibited interferon-gamma, and upregulated the secretion level of interleukin-10. Its knockdown had the opposite effect. FN1 was identified as an interacting protein of FGL1 and was positively regulated by FGL1 to promote the growth of RT4 cells. In the FGL1-induced tumor immunosuppressive microenvironment, blocking FN1 reversed the situation. In vivo studies showed that FGL1 silencing inhibited the growth of subcutaneously transplanted tumors in mice, which was related to the inhibition of FGL1 and FN1 expression. Conclusion: FGL1 promotes bladder cancer immune evasion by upregulating FN1. Our results provide a new reference for the immunotherapy of bladder cancer.
- Open Access
- 8 May 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102373
Impact of Muscle Depletion on Prognosis in Patients Undergoing Radical Cystectomy
- 8 May 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (4) , 102373
Open AccessImpact of Muscle Depletion on Prognosis in Patients Undergoing Radical Cystectomy
- Open Access
- 2 May 2025
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 21 (2) , 344-353
Research advances in FGL1/LAG3 for cancer diagnosis and treatment: From basics to clinical practice
Fibrinogen-like protein 1 (FGL1), a liver-secreted protein involved in proliferation and metabolism, and lymphocyte activation gene 3 (LAG3), an immune checkpoint receptor expressed on the surfaces of various activated immune cells, play critical roles in tumor immunology. Numerous studies have confirmed that FGL1 acts as a ligand for LAG3 and mediates immune evasion by tumor cells. This review aims to provide a comprehensive summary of the research progress in FGL1/LAG3 in terms of its expression, role in the tumor microenvironment, and clinical application. The expression and regulation of FGL1/LAG3 are influenced by multiple cytokines and signaling pathways. In the tumor microenvironment, FGL1/LAG3 modulates tumor cell proliferation, invasion, and migration through mechanisms such as epithelial-mesenchymal transition, gene methylation, oxygen metabolism, and lipid metabolism. FGL1/LAG3 can serve as a prognostic biomarker, independently or in combination with PD-L1/PD-1, and can be targeted using monoclonal antibodies, bi-specific antibodies, and dual-targeted vaccines to restore the proliferation and activation potential of T cells. Additionally, FGL1/LAG3 has demonstrated therapeutic potential when combined with targeted therapies, radiotherapy, traditional Chinese medicine, and adoptive cell therapy. Overall, FGL1/LAG3 plays a pivotal role in cancer initiation, progression, diagnosis, treatment, and prognosis.
- 2 May 2025
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 21 (2) , 344-353
Open AccessResearch advances in FGL1/LAG3 for cancer diagnosis and treatment: From basics to clinical practice
Fibrinogen-like protein 1 (FGL1), a liver-secreted protein involved in proliferation and metabolism, and lymphocyte activation gene 3 (LAG3), an immune checkpoint receptor expressed on the surfaces of various activated immune cells, play critical roles in tumor immunology. Numerous studies have confirmed that FGL1 acts as a ligand for LAG3 and mediates immune evasion by tumor cells. This review aims to provide a comprehensive summary of the research progress in FGL1/LAG3 in terms of its expression, role in the tumor microenvironment, and clinical application. The expression and regulation of FGL1/LAG3 are influenced by multiple cytokines and signaling pathways. In the tumor microenvironment, FGL1/LAG3 modulates tumor cell proliferation, invasion, and migration through mechanisms such as epithelial-mesenchymal transition, gene methylation, oxygen metabolism, and lipid metabolism. FGL1/LAG3 can serve as a prognostic biomarker, independently or in combination with PD-L1/PD-1, and can be targeted using monoclonal antibodies, bi-specific antibodies, and dual-targeted vaccines to restore the proliferation and activation potential of T cells. Additionally, FGL1/LAG3 has demonstrated therapeutic potential when combined with targeted therapies, radiotherapy, traditional Chinese medicine, and adoptive cell therapy. Overall, FGL1/LAG3 plays a pivotal role in cancer initiation, progression, diagnosis, treatment, and prognosis.
- Open Access
- 2 March 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-11
Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
The purpose of this meta-analysis is to determine the survival benefits and pathological outcomes of neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) administered to patients with cT2 or cT3-4N0M0 muscle-invasive bladder cancer (MIBC). PubMed, Embase, and the Cochrane Library were searched for comparing the use of NAC in combination with RC and RC alone in patients with different MIBC stages. A fixed effects model was used to calculate hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CIs), and the statistic was used to assess heterogeneity. Moreover, we determined possible sources of heterogeneity by subgroup and sensitivity analyses. Fifteen studies were finally selected. For cT2 bladder cancer, NAC combined with RC significantly increased the rates of pathological complete response (pCR) ( , 95% CI: 1.18–19.92, ) but did not improve overall survival (OS) ( , 95% CI: 0.72–1.02, ) across six studies. Regarding cT3-4 bladder cancer, NAC has a significantly improved effect on OS ( ; 95% CI: 0.59–0.81, , across seven studies and 5726 patients) and pCR (pooled ; 95% CI: 2.06–11.23, , across two studies) than RC alone. Most studies were randomized prospective trials (level 1 evidence), and all the effects were irrespective of the type of study design and did not vary between subgroups of patients. In conclusion, NAC combined with RC is recommended for patients with T3-4aN0M0 but not for patients with T2N0M0.
- 2 March 2022
- Published by Wiley in Disease Markers
- Vol. 2022, 1-11
Open AccessNeoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
The purpose of this meta-analysis is to determine the survival benefits and pathological outcomes of neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) administered to patients with cT2 or cT3-4N0M0 muscle-invasive bladder cancer (MIBC). PubMed, Embase, and the Cochrane Library were searched for comparing the use of NAC in combination with RC and RC alone in patients with different MIBC stages. A fixed effects model was used to calculate hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CIs), and the statistic was used to assess heterogeneity. Moreover, we determined possible sources of heterogeneity by subgroup and sensitivity analyses. Fifteen studies were finally selected. For cT2 bladder cancer, NAC combined with RC significantly increased the rates of pathological complete response (pCR) ( , 95% CI: 1.18–19.92, ) but did not improve overall survival (OS) ( , 95% CI: 0.72–1.02, ) across six studies. Regarding cT3-4 bladder cancer, NAC has a significantly improved effect on OS ( ; 95% CI: 0.59–0.81, , across seven studies and 5726 patients) and pCR (pooled ; 95% CI: 2.06–11.23, , across two studies) than RC alone. Most studies were randomized prospective trials (level 1 evidence), and all the effects were irrespective of the type of study design and did not vary between subgroups of patients. In conclusion, NAC combined with RC is recommended for patients with T3-4aN0M0 but not for patients with T2N0M0.
- Open Access
- 15 September 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-7
Urine Culture in Hospitalized Patients during 2014-2018: An Analysis on Pathogen Distribution and Drug Sensitivity
Objective. We sought to analyze the distribution and antibiotic sensitivity of pathogens in hospitalized patients and to provide a scientific reference for the rational application of antibiotics. Methods. From January 2014 to December 2018, urine cultures from patients in our hospital were collected and analyzed retrospectively for the presence, distribution, and drug sensitivity of pathogens. Results. A total of 42,854 midstream urine cultures were collected from which 11,891 (27.75) pathogens were isolated, including 8101 (68.13) strains of gram-negative bacteria, 2580 (21.69) strains of gram-positive bacteria, and 1210 (10.18) strains of fungi. Escherichia coli and Enterococci were the most common species of gram-negative and gram-positive bacteria, respectively. Drug sensitivity varied among different pathogens. Clear drug resistance was observed in bacteria, while fungus exhibited relatively lower resistance. Conclusion. Pathogens responsible for urinary tract infections in hospitalized patients are diversiform and display resistance to some antibiotics. Drug resistance monitoring should be enhanced to optimize antimicrobial therapy.
- 15 September 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-7
Open AccessUrine Culture in Hospitalized Patients during 2014-2018: An Analysis on Pathogen Distribution and Drug Sensitivity
Objective. We sought to analyze the distribution and antibiotic sensitivity of pathogens in hospitalized patients and to provide a scientific reference for the rational application of antibiotics. Methods. From January 2014 to December 2018, urine cultures from patients in our hospital were collected and analyzed retrospectively for the presence, distribution, and drug sensitivity of pathogens. Results. A total of 42,854 midstream urine cultures were collected from which 11,891 (27.75) pathogens were isolated, including 8101 (68.13) strains of gram-negative bacteria, 2580 (21.69) strains of gram-positive bacteria, and 1210 (10.18) strains of fungi. Escherichia coli and Enterococci were the most common species of gram-negative and gram-positive bacteria, respectively. Drug sensitivity varied among different pathogens. Clear drug resistance was observed in bacteria, while fungus exhibited relatively lower resistance. Conclusion. Pathogens responsible for urinary tract infections in hospitalized patients are diversiform and display resistance to some antibiotics. Drug resistance monitoring should be enhanced to optimize antimicrobial therapy.
- Open Access
- 18 January 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-10
A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer
Increasing evidence demonstrated that noncoding RNA is abnormally expressed in cancer tissues and serves a vital role in tumorigenesis, tumor development, and metastasis. The aim of the present study was to determine an lncRNA signature in order to predict the overall survival (OS) of patients with muscle-invasive bladder cancer (MIBC). A total of 246 patients with pathologically confirmed MIBC in The Cancer Genome Atlas (TCGA) dataset were recruited and included in the present study. We choose patients who have smoked less (including never smoking) or more than 15 years. A total of 44 differentially expressed lncRNAs were identified with a fold change larger than 1.5 and a value < 0.05 through the limma package. Subsequently, a comparison between patients with no tobacco smoke exposure for 15 years was performed by using the matchIt package. Among the 44 differentially expressed lncRNAs, 5 lncRNAs were identified to be significantly associated with OS. Based on the characteristic risk scores of these 5 lncRNAs, patients were divided into low-risk and high-risk groups and exhibited significant differences in OS. Multivariate Cox regression analysis demonstrated that the 5-lncRNA signature was independent of age, tumor-node metastasis (TNM) staging, lymphatic node status, and adjuvant postoperative radiotherapy. In the present study, a novel 5-lncRNA signature was developed and was demonstrated to be useful in predicting the survival of patients with MIBC. If validated, this lncRNA signature may assist in the selection of a high-risk subpopulation that requires more aggressive therapeutic intervention. The risk scores involved in several associated pathways were identified using gene set enrichment analysis (GSEA). However, the clinical implications and mechanism of these 5 lncRNAs require further investigation.
- 18 January 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-10
Open AccessA 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer
Increasing evidence demonstrated that noncoding RNA is abnormally expressed in cancer tissues and serves a vital role in tumorigenesis, tumor development, and metastasis. The aim of the present study was to determine an lncRNA signature in order to predict the overall survival (OS) of patients with muscle-invasive bladder cancer (MIBC). A total of 246 patients with pathologically confirmed MIBC in The Cancer Genome Atlas (TCGA) dataset were recruited and included in the present study. We choose patients who have smoked less (including never smoking) or more than 15 years. A total of 44 differentially expressed lncRNAs were identified with a fold change larger than 1.5 and a value < 0.05 through the limma package. Subsequently, a comparison between patients with no tobacco smoke exposure for 15 years was performed by using the matchIt package. Among the 44 differentially expressed lncRNAs, 5 lncRNAs were identified to be significantly associated with OS. Based on the characteristic risk scores of these 5 lncRNAs, patients were divided into low-risk and high-risk groups and exhibited significant differences in OS. Multivariate Cox regression analysis demonstrated that the 5-lncRNA signature was independent of age, tumor-node metastasis (TNM) staging, lymphatic node status, and adjuvant postoperative radiotherapy. In the present study, a novel 5-lncRNA signature was developed and was demonstrated to be useful in predicting the survival of patients with MIBC. If validated, this lncRNA signature may assist in the selection of a high-risk subpopulation that requires more aggressive therapeutic intervention. The risk scores involved in several associated pathways were identified using gene set enrichment analysis (GSEA). However, the clinical implications and mechanism of these 5 lncRNAs require further investigation.
- Open Access
- 3 September 2019
- Published by Wiley in Disease Markers
- Vol. 2019, 1-15
Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
This study was performed to identify the prognostic impact of lymphovascular invasion (LVI) in patients with upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). A systematic search in PubMed, Embase, and the Cochrane Library was performed to identify relevant studies. The outcomes of interest, including progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were extracted, and the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used for effect size estimation. Subgroup, metaregression, and sensitivity analyses were performed to explore potential origins of heterogeneity. Publication bias was estimated by Egger’s linear regression and funnel plot. Our meta-analysis included a total of 27 studies involving 17,453 patients. The pooled HRs were statistically significant for PFS (, –2.11), CSS (, –2.27), and OS (, –1.87), with high heterogeneity (, 70.3%, and 59.2%, respectively). Four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3–T4). The fixed effects model () showed that the pooled HR was 1.64 (–1.99) for CSS. Egger’s plots showed no significant publication bias (PFS: , CSS: , and OS: ). Our meta-analysis demonstrated that LVI is a poor prognostic factor for UTUC and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality.- 3 September 2019
- Published by Wiley in Disease Markers
- Vol. 2019, 1-15
Open AccessPrognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
This study was performed to identify the prognostic impact of lymphovascular invasion (LVI) in patients with upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). A systematic search in PubMed, Embase, and the Cochrane Library was performed to identify relevant studies. The outcomes of interest, including progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were extracted, and the pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used for effect size estimation. Subgroup, metaregression, and sensitivity analyses were performed to explore potential origins of heterogeneity. Publication bias was estimated by Egger’s linear regression and funnel plot. Our meta-analysis included a total of 27 studies involving 17,453 patients. The pooled HRs were statistically significant for PFS (, –2.11), CSS (, –2.27), and OS (, –1.87), with high heterogeneity (, 70.3%, and 59.2%, respectively). Four studies explored the prognostic value of LVI in patients with advanced tumor stages (T3–T4). The fixed effects model () showed that the pooled HR was 1.64 (–1.99) for CSS. Egger’s plots showed no significant publication bias (PFS: , CSS: , and OS: ). Our meta-analysis demonstrated that LVI is a poor prognostic factor for UTUC and is strongly associated with disease recurrence, cancer-specific mortality, and overall mortality. - Open Access
- 7 July 2019
- Published by Hindawi Limited in Disease Markers
- Vol. 2019, 1-4
Response to: Comment on “Sex Differences in the Association between Night Shift Work and the Risk of Cancers: A Meta-Analysis of 57 Articles”
- 7 July 2019
- Published by Hindawi Limited in Disease Markers
- Vol. 2019, 1-4
Open AccessResponse to: Comment on “Sex Differences in the Association between Night Shift Work and the Risk of Cancers: A Meta-Analysis of 57 Articles”
- Open Access
- 6 June 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (2) , 1442-1450
Significance of cyclooxygenase‑2, prostaglandin E2 and CD133 levels in sunitinib‑resistant renal cell carcinoma
The current study investigated the mechanism underlying sunitinib resistance. The parental human renal cell carcinoma (RCC) cell line 786‑O was continuously exposed to various doses of sunitinib to obtain sunitinib‑resistant cells (786‑O/S). Cell proliferation and colony formation assays were performed to assess the survival of 786‑O/S cells. The half‑inhibitory concentration for the drug‑resistant cells was calculated. 786‑O/S cells demonstrated notably morphological changes compared with parental cells. Compared with 786‑O cells, 786‑O/S cells exhibited stronger proliferative and colony‑forming abilities. Western blot analysis was performed to measure the levels of cyclooxygenase 2 (COX‑2) and prostaglandin E2 (PGE2). Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression of COX‑2 and cluster of differentiation (CD) 133 in both 786‑O and 786‑O/S cells. Following incubation of the two cell lines with celecoxib, a COX‑2 inhibitor, RT‑qPCR was performed to detect the expression of COX‑2 and CD133, and western blot analysis was used to assess the expression of CD133. The results revealed that the levels of COX‑2 and PGE2 were significantly higher in 786‑O/S cells compared with 786‑O cells (P<0.01). Similarly, the expression of CD133 was 24‑fold higher in 786‑O/S compared with the parental cells (P<0.01). When celecoxib was incubated with the two cell lines, the expression of COX‑2 and CD133 decreased significantly (P<0.0001). In summary, the results indicate that activation of the COX‑2‑PGE2 pathway in RCC leads to the development of sunitinib resistance and may serve an important role in the maintenance of the characteristics of stem cells that are closely associated with drug resistance.
- 6 June 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (2) , 1442-1450
Open AccessSignificance of cyclooxygenase‑2, prostaglandin E2 and CD133 levels in sunitinib‑resistant renal cell carcinoma
The current study investigated the mechanism underlying sunitinib resistance. The parental human renal cell carcinoma (RCC) cell line 786‑O was continuously exposed to various doses of sunitinib to obtain sunitinib‑resistant cells (786‑O/S). Cell proliferation and colony formation assays were performed to assess the survival of 786‑O/S cells. The half‑inhibitory concentration for the drug‑resistant cells was calculated. 786‑O/S cells demonstrated notably morphological changes compared with parental cells. Compared with 786‑O cells, 786‑O/S cells exhibited stronger proliferative and colony‑forming abilities. Western blot analysis was performed to measure the levels of cyclooxygenase 2 (COX‑2) and prostaglandin E2 (PGE2). Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect the expression of COX‑2 and cluster of differentiation (CD) 133 in both 786‑O and 786‑O/S cells. Following incubation of the two cell lines with celecoxib, a COX‑2 inhibitor, RT‑qPCR was performed to detect the expression of COX‑2 and CD133, and western blot analysis was used to assess the expression of CD133. The results revealed that the levels of COX‑2 and PGE2 were significantly higher in 786‑O/S cells compared with 786‑O cells (P<0.01). Similarly, the expression of CD133 was 24‑fold higher in 786‑O/S compared with the parental cells (P<0.01). When celecoxib was incubated with the two cell lines, the expression of COX‑2 and CD133 decreased significantly (P<0.0001). In summary, the results indicate that activation of the COX‑2‑PGE2 pathway in RCC leads to the development of sunitinib resistance and may serve an important role in the maintenance of the characteristics of stem cells that are closely associated with drug resistance.